Lund, Sweden, January 7, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that Søren Bregenholt, Chief Executive Officer, will participate and host one-on-one investor meetings at the following upcoming investor conferences:
H.C. Wainwright BioConnect Conference, US
Location: Virtual Event
Date: January 10-13
The presentation will be available online – January 10-13, 2022.
Please visit the conference linkto register and view the event.
Redeye Fight Cancer Seminar – Outlook 2022
Location: Virtual Event
Date: Thursday, January 20, 2022
Time: 9:00 – 16:00, company presentation schedule will be updated by Redeye closer to the event and will be live broadcasted at Fight Cancer Seminar – Outlook 2022 | Redeye for Redeye members.
All presentations will be available via a digital library, which is accessible to event participants only. Please contact the organizers to if you wish to attend or Julie Silber if you wish to schedule a meeting with Alligator.
For further information, please contact:
Julie Silber, Investor Relations
Phone: +46 46-540 82 23
E-mail: jur@alligatorbioscience.com
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc. and several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, with MacroGenics Inc. and its RUBY™ bispecific platform with Orion Corporation. Out licensed programs include AC101, in Phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. Alligator Bioscience’s shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden. For more information, please visit http://www.alligatorbioscience.com.